TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04800042

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic test
Description: Blood iron status : ferritin and transferrin saturation factor
Study: NCT06019767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
Study: NCT06043687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice Paste
Description: Scaling and Root planing followed by dentifrice usage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice Paste
Description: Scaling and Root planing followed by dentifrice usage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice Paste
Description: Scaling and Root planing followed by dentifrice usage
Study: NCT06494150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Sirolimus
Description: nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days
Study: NCT06553118

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
Study: NCT05761639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: follow-up
Description: Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
Study: NCT05564377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT04903951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servoventilation (ASV) therapy
Description: Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Best medical treatment for stroke, including rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Best medical treatment for stroke, including rehabilitation
Study: NCT05001217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional medication
Description: Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medication
Description: Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine treatment
Description: 1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction
Study: NCT04856410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spaceflight
Description: Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spaceflight
Description: Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spaceflight
Description: Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controls
Description: No intervention
Study: NCT05339334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332/ritonavir will be given by mouth two times a day for 10 days
Study: NCT05710224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V181
Description: 0.5 mL SC dose of V181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Butantan-DV
Description: 0.5 mL SC dose of Butantan-DV
Study: NCT03516968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly bolus of cholecalciferol per os
Description: Bolus therapy (100'000 - 200'000 IU/month depending on age: \< or ≥ 9 years old) for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily dose of cholecalciferol per os
Description: Daily substitution (3'500 to 6'500 IU/day depending on age: \< or ≥ 9 years old) for 3 months

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: no cholecalciferol therapy
Study: NCT05917509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/3TC
Description: DTG/3TC FDC will be administered as an oral once daily tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) LA
Description: CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) LA
Description: RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
Study: NCT06029907

Intervention type: OTHER
Group type: OTHER
Intervention: Smoking cessation and pain management intervention
Description: Patients will receive a behavioral smoking cessation and pain management intervention

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Patients will receive varenicline prescribed by their oncologist
Study: NCT06190613

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combination Peer navigation and mHealth intervention
Description: Peer navigation and SMS text message medication reminders (adapted to YMSM and YTW in community outreach-based delivery approach)
Study: NCT05174767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMDS
Description: AMDS Implantation
Study: NCT05713383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Feedback
Description: Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
Study: NCT05788666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GeriKit Mobile Application
Description: Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
Study: NCT04812093

Intervention type: DEVICE
Intervention: Spectroscopic otoscope measurements
Description: Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
Study: NCT05564377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutation Carrier Screening
Description: Undergo tumor mutational screening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mutation Carrier Screening
Description: Undergo tumor mutational screening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neratinib Maleate
Description: Given PO
Study: NCT05806294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Metabolic Rehabilitation
Description: Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
Study: NCT05669352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-4948
Description: Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
Study: NCT05564377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib Hydrochloride Monohydrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotorasib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study: NCT05047172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Aspirin
Description: ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
Study: NCT06187090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form
Description: Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
Study: NCT06410235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation and exercise program
Description: The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: The group received exercise
Study: NCT05828394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DFGG
Description: Depithelised free gingival graft harvesting technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCTG
Description: Subepithelial connective tissue graft harvesting technique
Study: NCT05047172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Aspirin
Description: low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel + Aspirin
Description: clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Factor Management
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Factor Management
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Risk Factor Management
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
Study: NCT06203600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo optional blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study: NCT05013957

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation analysis
Description: Methylation analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation analysis
Description: Methylation analysis
Study: NCT03913117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4aCRTE6E7L2
Description: Naked pNGVL4aCRTE6E7L2 DNA plasmid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4aCRTE6E7L2
Description: Naked pNGVL4aCRTE6E7L2 DNA plasmid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4aCRTE6E7L2
Description: Naked pNGVL4aCRTE6E7L2 DNA plasmid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4aCRTE6E7L2
Description: Naked pNGVL4aCRTE6E7L2 DNA plasmid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-CIN
Description: TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
Study: NCT06643793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome (ll) + 5-FU/LV + bevacizumab
Description: 1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w.
Study: NCT05255172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: 12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
Study: NCT05277740

Intervention type: DEVICE
Intervention: Eye-tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT04771442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction
Description: Single dose
Study: NCT04860453

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES via Illumina NextSeq 550 sequencing system
Description: Sequencing will be performed on an Illumina sequencing system

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva Sample
Description: Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample
Description: Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
Study: NCT06643897

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview
Description: 40-50 minute-qualitative interview.
Study: NCT06645145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orthographic facilitation
Description: Half of participants will receive orthographic support (text support) while learning new verbs. The investigators will compare learning with and without text support to determine if this aids verb learning.